<?xml version="1.0" encoding="UTF-8"?><xmi:XMI xmlns:xmi="http://www.omg.org/XMI" xmlns:pos="http:///de/tudarmstadt/ukp/dkpro/core/api/lexmorph/type/pos.ecore" xmlns:tcas="http:///uima/tcas.ecore" xmlns:cas="http:///uima/cas.ecore" xmlns:tweet="http:///de/tudarmstadt/ukp/dkpro/core/api/lexmorph/type/pos/tweet.ecore" xmlns:type8="http:///org/apache/uima/ruta/type.ecore" xmlns:morph="http:///de/tudarmstadt/ukp/dkpro/core/api/lexmorph/type/morph.ecore" xmlns:dependency="http:///de/tudarmstadt/ukp/dkpro/core/api/syntax/type/dependency.ecore" xmlns:type6="http:///de/tudarmstadt/ukp/dkpro/core/api/semantics/type.ecore" xmlns:type9="http:///org/apache/uima/trials/type.ecore" xmlns:noNamespace="http:///uima/noNamespace.ecore" xmlns:type="http:///de/tudarmstadt/ukp/dkpro/core/api/anomaly/type.ecore" xmlns:type7="http:///de/tudarmstadt/ukp/dkpro/core/api/syntax/type.ecore" xmlns:type3="http:///de/tudarmstadt/ukp/dkpro/core/api/metadata/type.ecore" xmlns:type4="http:///de/tudarmstadt/ukp/dkpro/core/api/ner/type.ecore" xmlns:type5="http:///de/tudarmstadt/ukp/dkpro/core/api/segmentation/type.ecore" xmlns:type2="http:///de/tudarmstadt/ukp/dkpro/core/api/coref/type.ecore" xmlns:constituent="http:///de/tudarmstadt/ukp/dkpro/core/api/syntax/type/constituent.ecore" xmlns:chunk="http:///de/tudarmstadt/ukp/dkpro/core/api/syntax/type/chunk.ecore" xmi:version="2.0"><cas:NULL xmi:id="0"/><tcas:DocumentAnnotation xmi:id="2" sofa="1" begin="0" end="2097" language="x-unspecified"/><type9:ORR xmi:id="3" sofa="1" begin="1003" end="1006"/><type9:PFSMean xmi:id="4" sofa="1" begin="1365" end="1375"/><type9:PFSTime xmi:id="5" sofa="1" begin="1451" end="1459"/><type9:PFSRate xmi:id="6" sofa="1" begin="1464" end="1468"/><type9:OSMean xmi:id="7" sofa="1" begin="1646" end="1658"/><type9:OSTime xmi:id="8" sofa="1" begin="1709" end="1717"/><type9:OSRate xmi:id="9" sofa="1" begin="1725" end="1729"/><cas:Sofa xmi:id="1" sofaNum="1" sofaID="_InitialView" mimeType="text" sofaString="BACKGROUND: Previous biochemotherapy regimens for metastatic melanoma have&#13;&#10;required attenuated dosages of interleukin 2 (IL-2) that may have compromised&#13;&#10;efficacy.&#13;&#10;METHODS: In a phase 2 study, the authors tested sequential temozolomide (75 mg/m2&#13;&#10;per day orally for 3 weeks) followed by high-dose, IL-2 (600,000 U/kg per dose&#13;&#10;intravenously; maximum, 14 doses over 5 days).&#13;&#10;RESULTS: Thirty-eight patients with treatment-naive American Joint Committee on&#13;&#10;Cancer stage IV melanoma (8 patients with M1a disease, 6 patients with M1b&#13;&#10;disease, and 24 patients with M1c disease) were enrolled. Ten patients had a&#13;&#10;history of treated brain metastases. Thirty-one patients who received at least 2 &#13;&#10;cycles of IL-2 were evaluable for response. Grade 3 toxicities included&#13;&#10;hyperbilirubinemia (9 patients), hematologic toxicities (leukopenia in 5&#13;&#10;patients, thrombocytopenia in 3 patients), diarrhea (2 patients), and oliguria (1&#13;&#10;patient). One patient had grade 4 nausea. The overall response rate (ORR) was 16%&#13;&#10;and included 3 complete responses that lasted 10.8 months, &gt; or =32 months, and &gt;&#13;&#10;or =36 months and 2 partial responses that lasted 13 months and 14 months.&#13;&#10;Responses were observed in patients with M1a disease and in patients with M1c&#13;&#10;disease. Sixteen patients had stable disease (15 patients progressed). The median&#13;&#10;progression-free survival (PFS) was 5.3 months (95% confidence interval [CI],&#13;&#10;3.7-7.5 months). The probability of PFS at 6 months was 0.52 (95% CI, 0.33-0.67).&#13;&#10;Among 38 enrolled patients, 16 patients remained alive at a median follow-up of&#13;&#10;6.7 months (range, 1.9-36.1 months). The median overall survival (OS) was 12.1&#13;&#10;months (95% CI, 9.1-16.4 months), and the probability of 12-month OS was 0.54&#13;&#10;(95% CI, 0.34-0.70 months).&#13;&#10;CONCLUSIONS: The current results indicated that it is safe to administer HD IL-2 &#13;&#10;sequentially with temozolomide and that this combination has lower toxicity than &#13;&#10;previously used concurrent biochemotherapy regimens. However, The ORR and the&#13;&#10;durability of responses with this combination did not exceed those of&#13;&#10;single-agent HD IL-2."/><cas:View sofa="1" members="2 3 4 5 6 7 8 9"/></xmi:XMI>